v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
OPERATING ACTIVITIES:    
Net loss $ (7,469) $ (3,933)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 330 868
Gain on sale of Orthobiologics Business (425)  
Loss (gain) on revaluation of warrant liability 1,655 (5,187)
Amortization of deferred financing costs and debt discount   53
Interest expense recorded as additional revenue interest obligation or long-term debt 145 702
Stock-based compensation 931 1,211
Changes in right-of-use assets and lease liabilities and lease incentives received 320 (103)
Changes in operating assets and liabilities:    
Accounts receivable (334) (584)
Inventory (40) (375)
Receivables of litigation costs (502) 867
Prepaid expenses and other 241 449
Accounts payable and accrued expenses 542 (225)
Contingent liability for legal proceedings (3,225) (2,624)
Net cash used in operating activities (7,831) (8,881)
INVESTING ACTIVITIES:    
Proceeds from sale of Orthobiologics Business 425  
Expenditures for property and equipment (459) (278)
Net cash used in investing activities (34) (278)
FINANCING ACTIVITIES:    
Proceeds from direct registered offering and warrants, net of offering costs   13,796
Repayments of insurance premium financings   (446)
Payments for taxes upon vesting of restricted stock units (44) (152)
Proceeds from stock option exercises and issuance common stock under ESPP 47 80
Net cash provided by financing activities 3 13,278
Net (decrease) increase in cash and cash equivalents (7,862) 4,119
Cash and cash equivalents, beginning of period 36,350 13,239
Cash and cash equivalents, end of period 28,488 17,358
Supplemental Cash Flow and Non-Cash Financing Activities Disclosures:    
Cash paid for interest   $ 526
Conversion of Prefunded Warrants to common stock $ 1,390